Structure-Guided Design of a Selective Bcl-Xl InhibitorLessene, G.L., Czabotar, P.E., Sleebs, B.E., Zobel, K., Lowes, K.L., Adams, J.M., Baell, J.B., Colman, P.M., Deshayes, K., Fairbrother, W.J., Flygare, J.A., Gibbons, P., Kersten, W.J.A., Kulasegaram, S., Moss, R.M., Parisot, J.P., Smith, B.J., Street, I.P., Yang, H., Huang, D.C.S., Watson, K.G.
(2013) Nat Chem Biol 9: 390-397
- PubMed: 23603658
- DOI: https://doi.org/10.1038/nchembio.1246
- Primary Citation of Related Structures:
3ZK6, 3ZLN, 3ZLO, 3ZLR
- PubMed Abstract:
The prosurvival BCL-2 family protein BCL-X(L) is often overexpressed in solid tumors and renders malignant tumor cells resistant to anticancer therapeutics. Enhancing apoptotic responses by inhibiting BCL-X(L) will most likely have widespread utility in cancer treatment and, instead of inhibiting multiple prosurvival BCL-2 family members, a BCL-X(L)-selective inhibitor would be expected to minimize the toxicity to normal tissues. We describe the use of a high-throughput screen to discover a new series of small molecules targeting BCL-X(L) and their structure-guided development by medicinal chemistry. The optimized compound, WEHI-539 (7), has high affinity (subnanomolar) and selectivity for BCL-X(L) and potently kills cells by selectively antagonizing its prosurvival activity. WEHI-539 will be an invaluable tool for distinguishing the roles of BCL-X(L) from those of its prosurvival relatives, both in normal cells and notably in malignant tumor cells, many of which may prove to rely upon BCL-X(L) for their sustained growth.
Chemical Biology Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia. firstname.lastname@example.org